ArticleDigestive diseases and sciences2023

Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease.

Carl Eriksson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.